Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Na Cui, Hao Wang, Longxiang Su, Haibo Qiu, Ruoyu Li, Dawei Liu and on behalf of the China-SCAN Team

Abstract

Background: To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive Candida infections (ICIs) in intensive care units (ICUs) in China.

Methods: A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric, pre-emptive, and targeted therapy were adopted based on starting criteria including clinical, microbiological, and other conventional prediction rules. The primary outcome was hospital mortality and the secondary endpoints were duration days in ICU and duration days in hospital. The global responses (clinical and microbiological) at the end of the empirical therapy were also assessed.

Results: A total of 268/306 (87.6%) ICI patients received antifungal therapy, including 142/268 (53.0%) initial empirical therapy, 53/268 (19.8%) initial pre-emptive therapy, and 73/268 (27.2%) initial targeted therapy. Compared with the initial empirical antifungal therapy and targeted antifungal therapy, patients with initial pre-emptive antifungal therapy had significantly less clinical remission [11/53 (21.2%) vs. 61/142 (43.3%) vs. 61/142 (43.3%), P = 0.009], higher ICU [26/53 (57.8%) vs. 42/142 (32.2%) vs. 27/73 (43.5%), P = 0.008] and hospital mortality [27/53 (60.0%) vs. 43/142 (32.8%) vs. 29/73 (46.8%), P = 0.004] and more microbiological persistence [9/53 (17.0%) vs. 6/142 (4.2%) vs. 9/73 (12.3%), P = 0.011]. Kaplan-Meier survival analysis revealed that ICI patients with initial pre-emptive antifungal therapy and targeted antifungal therapy were associated with reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation of fungal infection (log-rank test: P = 0.021). Multivariate regression analysis provided evidence that initial empirical antifungal therapy was an independent predictor for decreasing the hospital mortality in ICI patients on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667, P = 0.002; odds ratio 0.351, 95% confidence interval 0.168–0.735, P = 0.006).

Conclusions: The initial therapeutic strategy for invasive candidiasis was independently associated with hospital mortality. Prompt empirical antifungal therapy could be critical to decrease early hospital mortality.

Trial registration: Clinicaltrials.gov NCT01253954 (retrospectively registration date: December 3, 2010)

Keywords: Invasive Candida infection, Initial therapeutic strategy, Clinical outcome, ICU
Background
Invasive fungal infection (IFI) is one of the most common in opportunistic infections for critically ill patients [1]. Recently, IFI incidences in intensive care units (ICUs) have increased year by year with improvements in hygiene, disease management, and life support technology [2]. Invasive candidiasis infection (ICI) is the most common and important part of IFI [3, 4]. Candidemia is responsible for 7–10% of nosocomial bloodstream infections, and Candida is located in the top five most common pathogens [5–7]. The 6.9 per 1000 candidemia incidence of ICU patients and 7.5% of prevalence of antifungal agents administered have been reported [8, 9]. ICI, mostly candidemia, increases the mortality rate, represents longer lengths of ICU or hospital stay, and uses a great deal of healthcare expenses and resources [3, 4, 10]. Thus, finding an appropriate treatment strategy for the best ICI treatment is an issue that needs to be resolved.

Anti-infection strategies for ICI are complex processes that include both clinical diagnosis and treatment; delayed treatments worsen the prognosis, drug abuse leads to antimicrobial drug selection pressure, and wasting resources is an important clinical problem. Faced with ICIs in critically ill patients, we urgently need to know whether giving early empirical antifungal therapy, then adjusting according to clinical diagnosis circumstances, or waiting for the microbiological evidence to determine the start of the antifungal treatment is acceptable or not. Additionally, knowing the types of evidence to collect before we begin antifungal therapy would benefit patients’ prognoses [direct culture detection or surrogate markers, such as Candida mannan antigens and antimmann antibodies and β-D-glucan, or polymerase-chainreaction (PCR) assays]. Although many experts and proposed guidelines suggest prophylaxis, empirical, pre-emptive, targeted, and other various initial antifungal treatment strategies, there is no currently available evidence for the effectiveness of previously mentioned treatments in ICU patients. The China Survey of Candidiasis in the ICU (China-SCAN) study was performed to assess the current incidence, mortality, pathogen spectrum, management, treatment, and risk factors for ICI in China’s ICUs [11]. The data from the China-SCAN study were used to investigate the impact of an initial antifungal therapeutic strategy on the prognosis of patients with ICIs in Chinese ICUs. We expect this study to provide a reasonable basis for how to select antifungal therapy strategies clinically.

Methods
Study design and patients involved
The China-SCAN study is the largest observational study on prevalence of ICI in China and was conducted between November 2009 and April 2011 in 67 participating ICUs distributed throughout China. The details of this study, including the study population, inclusion, and exclusion criteria were previously published [11]. All participating hospitals accepted the central ethics committee (Ethics Committee of Zhongda Hospital of Southeast University) review or conducted a further, independent, ethics review according to their own institutional policy. This was registered with ClinicalTrials.gov (NCT01253954). During the China-SCAN trial, 306 out of 96,060 ICU patients from 67 centers throughout China were diagnosed with ICIs by direct detection of fungal infection. A total of 268/306 (87.6%) patients finally received antifungal therapy. The remaining 59 patients withdrew from or decided to forego comprehensive treatment, 29 of whom died in the hospital and 30 of whom were discharged at their request. Based on the initial antifungal therapeutic strategies received, all the patients included were divided into empirical (n = 142), pre-emptive (n = 53), and targeted (n = 73) therapy groups. Based on the clinical prognosis of patients who died in the hospital or completed treatment and were discharged at their physician’s discretion, the population was further divided into survivor (n = 139) and non-survivor (n = 99) groups. Figure 1 presents a flowchart of patient screening and selection for this study.

Evidence for antifungal treatment and initial antifungal therapy strategy
Definition of infection
Based on the guidelines for the diagnosis and management of candidiasis issued by the Infectious Diseases Society of America [12] and the European Society of Clinical Microbiology and Infectious Diseases [13], the evidence used to treat antifungal infection in the China-SCAN trial was divided into the following four categories:

(a) Clinical signs of infection diagnosed by the opinion of treating physician had to meet two or more of the following clinical features [14]: (i) body temperature ≥ 38 or < 36 °C; (ii) respiratory rate ≥ 30 breaths per min; (iii) pulse rate ≥ 120 beats per min; and (iv) abnormal total peripheral white blood cell counts ≥ 10,000 or < 4000 per mm$^3$, or immature neutrophils > 15%.

(b) Risk factors of fungal infection: etiology-related factors such as neutropenia, hemato logical diseases, transplantation, surgery, and tumors; treatment-related factors, such as parenteral nutrition, broad-spectrum antibiotics, venous indwelling catheters, and other factors causing increased rate of fungal infection.

(c) Microbiological evidence: Indirect evidence of fungal infections: serological parameters including...
Galactomannan and β-D-glucan. The fungal colonization index was calculated [15]. The *Candida* colonization index (CCI) was calculated as the ratio of the number of culture-positive surveillance sites to the total number of sites cultured. A CCI ≥ 0.5 was considered as indirect evidence of invasive candidiasis in this study. Direct detection of fungal infections: blood and tissue specimens obtained from normally sterile sites were cultured. One thing to be mentioned, fungal combined bacterial infection, or even viral infection occurred in one patient maybe exist. So co-infection were not be systematically excluded.

### Treatment options and outcomes

By combining evidence for the antifungal treatments mentioned above and actual clinical situations in mainland China hospitals, initial antifungal therapy began when patients met the following clinical features based on personal choice of the physician: (1) Empirical antifungal therapy: the patients had clinical signs of infection with any of the risk factors of fungal infection; (2) Pre-emptive antifungal therapy: the patients must have at least one indirect evidence of a fungal infection; (3) Targeted antifungal therapy: in addition to meeting the conditions for empirical antifungal therapy, the patients must have one direct evidence of a fungal infection.

Complete clinical efficacy was defined as elimination of all signs and symptoms of ICI, and accompanying radiographic resolution; partial efficacy was defined as improvement rather than complete elimination. Microbiological elimination was defined as negative culture from the original infection site.

### Statistical analysis

Quantitative data with normal distributions are denoted as the means ± standard deviations. Student’s *t* test or one-way analysis of variance (ANOVA) was performed to compare the means between the different groups. Abnormally distributed quantitative data were denoted using medians (interquartile ranges) and the rank-sum test was used to analyze these values. Data of unordered categories were denoted by rate, and differences in the rate between two groups were examined through a chi-square test. Survival curves for ICU and hospital duration were estimated using the Kaplan-Meier method, and a log rank (Mantel-Cox) test was used to estimate differences among these three antifungal therapies. Correlation between variables was tested by Spearman’s coefficient of rank correlation. Variables found to be significantly associated with mortality with a *P*-value < 0.01 at univariate analysis were introduced into a logistic stepwise regression model. All significant variables with collinearity were excluded from the regression model. When deciding which covariates to retain as candidate predictors for the multivariable model, we considered the clinical relevance of each covariate. The adjusted odds ratio of dying and the 95% confidence interval for all independent factors associated with mortality were calculated. Statistical analyses were performed with SPSS 16.0 (SPSS, Chicago, IL, USA), and a *P* value of < 0.05 was considered significant.
Results
Baseline characteristics and risk factors of fungal infection in ICI patients receiving antifungal therapy
Table 1 presents the baseline characteristics of the patients whose data were analyzed in this study. As shown in the table, there were no significant cross-group differences in terms of gender, body weight, hospital stays before ICU admission, ICU and hospital stays before candidiasis onset, Acute Physiology and Chronic Health Evaluation (APACHE) II score and sequential organ failure assessment (SOFA) score on ICU admission, and accompanying underlying diseases. However, the age of patients receiving initial targeted antifungal therapy was higher than other two groups. Table 2 lists the risk factors of fungal infection present within 2 weeks (3 months for immunosuppressants) prior to study entry, or at diagnosis, among 268 patients with ICI who received antifungal therapy in the China-SCAN study. The indwelling arterial catheterized in a significantly lower proportion of patients in targeted therapy group compared with other two groups (P < 0.05). The immunocompromised state, antibiotic therapy, clinical procedures including life-sustaining treatments ≥ 24 h, central venous catheterization, drainage and urethral catheterization, gastrointestinal dysfunction, parenteral nutrition, and surgery showed no significant differences among the different therapy strategies.

Microbiological and clinical characteristics of ICI patients receiving antifungal therapy
The candidiasis source of this study population was mainly bloodstream infections, which accounted for 95.9% (257/268) of infections. Comparing the sources of candidiasis among the three therapy strategies, only the targeted group had more abdominal candidiasis infections (P = 0.026). C. albicans (107, 39.9%), C. parapsilosis (42, 15.7%), C. tropicalis (37, 13.8%), and C. glabrata (37, 13.8%) were the most prevalent species isolated, with mixed infection were identified in 2/107 (1.9%), 1/42 (2.4%), 1/37 (2.7%), and 1/37 (2.7%) patients who received antifungal therapy in this study. Further Candida species were identified in < 2% of samples. 22 (8.2%) fungal isolates with proven yeast forms that were most suggestive of Candida spp. could not be further characterized. Based on microbiological determination of MIC, the susceptibility to antifungal treatment was 89.9% (241/268) and the

Table 1 Baseline characteristics of 268 ICI patients receiving antifungal therapy in the China-SCAN study

| Variables                        | Empirical | Pre-emptive | Targeted | P-value |
|----------------------------------|-----------|-------------|----------|---------|
| Age, years                       | 58.3 ± 21.6 | 58.3 ± 18.4 | 68.7 ± 16.2 | 0.001 |
| Gender, n (%)                    |           |             |          | 0.414  |
| Male                             | 98 (69.0) | 40 (75.5)   | 47 (64.4) |         |
| Female                           | 44 (31.0) | 13 (24.5)   | 26 (35.6) |         |
| Body weight, kg                  | 61.8 ± 10.7 | 63.5 ± 10.4 | 63.8 ± 10.1 | 0.473  |
| Hospital stays before ICU admission, days | 0.5 (10.0) | 1.0 (4.5)   | 0.0 (11.5) | 0.829  |
| ICU stays before candidiasis onset, days | 9.0 (17.0) | 10.0 (14.5) | 11.0 (33.0) | 0.717  |
| Hospital stays before candidiasis onset, days | 16.5 (23.3) | 12.0 (24.5) | 16.0 (41.0) | 0.461  |
| Underlying disease, n (%)        |           |             |          |         |
| Diabetic mellitus                | 28 (19.7) | 13 (24.5)   | 21 (28.8) | 0.318  |
| Chronic cardiac dysfunction a    | 23 (16.2) | 14 (26.4)   | 17 (23.3) | 0.210  |
| Chronic obstructive pulmonary disease | 15 (10.6) | 6 (11.3)    | 12 (16.4) | 0.449  |
| Chronic renal insufficiency b    | 12 (8.5)  | 5 (9.4)     | 13 (17.8) | 0.108  |
| Chronic hepatic insufficiency c   | 4 (2.8)   | 1 (1.9)     | 6 (8.2)   | 0.111  |
| Solid tumor                      | 26 (18.3) | 7 (13.2)    | 17 (23.3) | 0.353  |
| Haematological malignancy        | 2 (1.4)   | 1 (1.9)     | -         | 0.545  |
| Illness severity at ICU admission|           |             |          |         |
| APACHE II score                  | 20.0 ± 9.2 | 20.9 ± 8.1  | 21.5 ± 8.6 | 0.517  |
| SOFA score                       | 7.2 ± 3.7 | 7.7 ± 3.4   | 6.8 ± 3.8 | 0.434  |

Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)
APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment
aAll patients corresponding to the New York Heart Association (NYHA) standards of level II or higher
bAll patients receiving long-term hemodialysis
As described according to APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma
The complete resistance rate was 6% (15/268). There were no significant differences in the pathogenic Candida species, susceptibility and duration of initial antifungal medication between the three different treatment groups. However, the initial antifungal agents differed between the three groups, more caspofungin (37.7%) were used in pre-emptive group while more voriconazole (28.8%) were used in targeted group. Compared with empirical and targeted therapy group, the pre-emptive group showed significantly higher microbiological persistence ($P = 0.011$) and adjustment probability after initial antifungal therapy ($P < 0.05$).

In addition of microbiological characteristics, the clinical procedures and treatment outcomes of the 268 ICI patients who received antifungal therapy were also listed in the Table 3. There were no significant differences in the APACHE II score, vasopressor administration, and catheterization at ICI diagnosis between the three different strategy groups. The SOFA score at ICI diagnosis and immunopotentiation therapy including immunoglobulin and thymosin were significantly higher while the central venous catheter removed within 48 h after first positive sample obtained were significantly lower in pre-emptive group than in other two groups ($P < 0.05$).

Among the 268 ICI patients who received antifungal therapy, the majority of patients (193/268, 72.0%) experienced clinical improvement, while complete clinical remission occurred in only (94/268, 35.1%) patients. In total, 59 patients withdrew from or decided to forego comprehensive treatment, of whom 29 died in hospital and 30 were discharged at their request. The overall ICU or hospital mortality rates lists here were based on the

| Variables                                      | Empirical N = 142 | Pre-emptive N = 53 | Targeted N = 73 | P-value |
|------------------------------------------------|-------------------|--------------------|-----------------|---------|
| Immune compromised, n (%)                      |                   |                    |                 |         |
| Immunosuppressant therapy^a                    | 5 (3.5)           | 3 (5.7)            | 5 (6.8)         | 0.535   |
| HIV infection                                  | 1 (0.7)           | 1 (1.9)            |                 | 0.476   |
| Neutropenia                                    | 3 (2.1)           |                    |                 | 0.260   |
| Previous antibiotic therapy, n (%)^b           |                   |                    |                 |         |
| cephalosporins                                 | 38 (26.8)         | 9 (17.0)           | 12 (16.4)       | 0.138   |
| carbapenems                                    | 49 (34.5)         | 18 (34.0)          | 20 (27.4)       | 0.554   |
| penicillins                                    | 62 (43.7)         | 31 (59.6)          | 30 (41.1)       | 0.858   |
| quinolones                                     | 17 (12.0)         | 8 (15.1)           | 9 (12.3)        | 0.839   |
| glycopeptides                                  | 26 (18.3)         | 20 (38.0)          | 12 (16.4)       | 0.925   |
| Life-sustaining treatments ≥ 24 h              |                   |                    |                 |         |
| invasive mechanical ventilation                | 113 (79.6)        | 47 (88.7)          | 60 (82.2)       | 0.337   |
| vasopressor                                    | 47 (33.1)         | 12 (22.6)          | 19 (26.0)       | 0.286   |
| Renal replacement therapy                      | 8 (5.6)           | 5 (9.4)            | 8 (11.0)        | 0.345   |
| Catheterization, n (%)^c                       |                   |                    |                 |         |
| central venous                                 | 113 (79.6)        | 45 (84.9)          | 66 (90.4)       | 0.122   |
| indwelling arterial                            | 27 (19.6)         | 13 (25.0)          | 6 (8.5)         | 0.040   |
| drainage tube                                  | 52 (36.6)         | 26 (49.1)          | 23 (31.5)       | 0.124   |
| urethral                                       | 104 (73.8)        | 43 (81.1)          | 53 (73.6)       | 0.534   |
| Gastrointestinal dysfunction, n (%)^d          | 72 (50.7)         | 32 (60.4)          | 45 (61.6)       | 0.229   |
| Total parenteral nutrition, n (%)              | 70 (49.3)         | 30 (56.6)          | 41 (56.2)       | 0.513   |
| Surgery, n (%)                                 | 59 (41.5)         | 24 (45.3)          | 25 (34.7)       | 0.457   |
| Abdominal                                      | 33 (23.2)         | 20 (37.7)          | 18 (24.7)       | 0.114   |

Continuous variables are expressed as the means ± SD or medians (IQR). All the other data are raw numbers (%)

^aVariables included steroid therapy, which defined as > 0.5 mg/(kg·day)−1 prednisone over 1 month (n = 7), cancer chemotherapy (n = 6), post-solid organ transplant immunosuppression (n = 1), allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation (n = 1), and tumor necrosis factor therapy (n = 1) within 3 months prior to study entry

^bAll patients receiving systemic drug therapy for ≥ 3 days within 2 weeks prior to study entry

^cVariables included patients who required treatments were catheterized within 2 weeks of the first positive sample no matter the catheter was removed or not before diagnosis

^dVariables included hemorrhage, food intolerance, perforation, surgery, acalculous cholecystitis or intra-abdominal hypertension
Table 3 Microbiological and clinical characteristics among 268 ICI patients receiving antifungal therapy in the China-SCAN study

| Variables                                                                 | Empirical N=142 | Pre-emptive N=53 | Targeted N=73 | P-value  |
|---------------------------------------------------------------------------|-----------------|------------------|---------------|----------|
| Source of candidiasis, n (%)                                              |                 |                  |               |          |
| Blood                                                                      | 138 (97.2)      | 51 (96.2)        | 68 (93.2)     | 0.366    |
| Proven catheter-related                                                    | 12 (8.5)        | 10 (18.9)        | 7 (6.8)       | 0.056    |
| Abdominal                                                                  | 2 (1.4)         | 1 (1.9)          | 6 (8.2)       | 0.026    |
| Intracranial                                                              | 1 (0.7)         | 1 (1.9)          | 1 (1.4)       | 0.762    |
| Pulmonary                                                                  | -               | -                | -             | 0.131    |
| Pleural                                                                    | 1 (0.7)         | -                | -             | 0.641    |
| Pathogenic Candida species, n (%)                                          |                 |                  |               |          |
| C. albicans                                                               | 56 (39.4)       | 20 (37.7)        | 31 (42.5)     | 0.854    |
| C. tropicalis                                                              | 18 (12.7)       | 10 (18.9)        | 9 (12.3)      | 0.490    |
| C. glabrata                                                                | 18 (12.7)       | 11 (20.8)        | 8 (11.0)      | 0.247    |
| C. parapsilosis                                                            | 21 (14.8)       | 7 (13.2)         | 14 (19.2)     | 0.605    |
| Uncategorized                                                             | 11 (7.7)        | 5 (9.4)          | 6 (8.2)       | 0.930    |
| Initial antifungal therapy                                                |                 |                  |               |          |
| Categories, n (%)                                                         |                 |                  |               |          |
| fluconazole                                                                | 61 (43.0)       | 16 (30.2)        | 24 (32.9)     | 0.160    |
| caspofungin                                                                | 27 (19.0)       | 20 (37.7)        | 17 (23.3)     | 0.024    |
| voriconazole                                                               | 20 (14.1)       | 8 (15.1)         | 21 (28.8)     | 0.025    |
| Susceptibility, n (%)                                                      |                 |                  |               |          |
| susceptible                                                                | 125 (88.0)      | 48 (90.6)        | 68 (93.2)     | 0.490    |
| completely resistant                                                       | 9 (6.3)         | 3 (5.7)          | 3 (4.1)       | 0.797    |
| Duration, days                                                            | 8.5 (10.0)      | 6.0 (9.8)        | 7.0 (12.0)    | 0.932    |
| Drug Adjustment, n (%)                                                     | 67 (47.2)       | 35 (66.0)        | 30 (41.1)     | 0.017    |
| Procedures at diagnosis, n (%)                                            |                 |                  |               |          |
| APACHE II score                                                           | 195 ± 8.1       | 209 ± 8.8        | 212 ± 7.4     | 0.517    |
| SOFA score                                                                 | 6.7 ± 3.5       | 8.2 ± 4.1        | 6.2 ± 3.7     | 0.010    |
| Vasopressor                                                               | 44 (31.0)       | 18 (34.0)        | 21 (28.8)     | 0.824    |
| Catheterization, n (%)                                                     |                 |                  |               |          |
| central venous                                                            | 90 (64.7)       | 37 (69.8)        | 58 (79.5)     | 0.086    |
| indwelling arterial                                                       | 19 (13.8)       | 9 (17.3)         | 5 (7.0)       | 0.202    |
| drainage tube                                                             | 37 (26.8)       | 21 (42.0)        | 21 (29.6)     | 0.133    |
| urethral                                                                  | 100 (70.9)      | 41 (77.4)        | 52 (72.2)     | 0.668    |
| Central venous catheter removed within 48 h after first positive sample obtained, n (%) | 102 (71.8) | 28 (52.8) | 49 (67.1) | 0.043 |
| Drainage catheter removed within 48 h after first positive sample obtained, n (%) | 16 (11.3) | 6 (11.3) | 8 (11.0) | 0.997 |
| Immunopotentiation therapy, n (%)                                          | 55 (38.7)       | 32 (60.4)        | 34 (46.6)     | 0.025    |
| Microbiological evaluation, n (%)                                         |                 |                  |               |          |
| Eradication                                                                | 73 (51.4)       | 27 (50.9)        | 36 (49.3)     | 0.958    |
duration of hospital stay and ICU stay after infection did not significantly differ among the three groups, the empirical therapy group had the highest clinical complete remission, lowest ICU mortality and hospital mortality compared to the other two groups \((P < 0.01)\). From Kaplan-Meier analysis, the empirical therapy group had the highest survival probabilities after fungal infection for hospital duration \((P = 0.021)\) rather than ICU duration \((P = 0.117)\) (Fig. 2).

Clinical differences between survivors and non-survivors receiving antifungal therapy
Analysis of the risk factors for mortality revealed a higher risk with increasing age and higher APACHE II score and SOFA score on ICU admission \((P < 0.05)\). Among patients in the non-survivor group, the APACHE II score and SOFA score at the time of ICI diagnostic confirmation were significantly higher than those in the survivor group \((P < 0.01)\). Additionally, vasopressor administration and central venous catheterization at ICI diagnosis occurred in a significantly higher proportion of patients in the non-survivor group compared with patients in the survivor group \((P < 0.05)\). More importantly, the choice of initial antifungal therapy strategy differed significantly between the two groups \((P = 0.004)\), more patients received empirical antifungal therapy in survivors than in non-survivors \((P < 0.05)\) (Table 4).

Risk factors for hospital mortality in ICI patients receiving different antifungal therapy strategies
Variables found to be significantly associated with mortality with a \(P\) value < 0.01 at univariate analysis were introduced into a logistic stepwise regression model (Table 5). All significant variables with collinearity were excluded from the regression model. The first multivariate analysis was performed by introducing APACHE II and SOFA score on ICU admission as independent factors (Table 6) and the second one was performed by introducing APACHE II and SOFA score at ICI diagnosis as independent factors (Table 7). This was motivated by the fact that both the collinearity between APACHE II on ICU admission and at ICI diagnosis \((r^2 = 0.51, P < 0.001)\) and SOFA score on ICU admission and at ICI diagnosis \((r^2 = 0.48, P < 0.001)\) were high.

The results showed that the APACHE II score on ICU admission (odds ratio 1.047, \(P = 0.004\)), which suggested a risk factor for poor prognosis. Compared with preemptive therapy strategy, the empirical therapy may be a protective factor for poor prognosis on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667, \(P = 0.002\); odds ratio 0.351, 95% confidence interval 0.168–0.735, \(P = 0.006\)).

Discussion
IFI is one of the common infections in the ICU with a high level of mortality rate. A large number of studies of anti-bacterial infection treatment suggested that prompt early empirical strategies of antibiotic usage is an important factor affecting anti-infection treatment effects and prognosis [16, 17]. However, whether this therapy strategy can be used in antifungal therapy remains unclear. In addition, previous studies relevant to the strategy of antifungal infections were carried out in fungal high-risk populations, including patients with non-fungal infections and confirmed fungal infections. Identification of patients at risk of Candida infections will inevitably impact the results for the appropriate antifungal treatment time. We selected 306 patients diagnosed with ICI from the China-SCAN study, which is the only study to assess antifungal therapy among patients in ICU diagnosed with ICIs. It excluded the high-risk patients with non-fungal infections, which maybe more
### Table 4
Risk factors for hospital mortality in 268 ICI patients receiving antifungal therapy in the China-SCAN study based only on patients who died in hospital or completed treatment and were discharged at their physician’s discretion

| Variables                                      | Survivors   | Non-survivors | P-value |
|------------------------------------------------|-------------|---------------|---------|
| Age, years                                     | 58.6 ± 20.6 | 66.0 ± 19.8   | 0.0006  |
| Gender, n (%)                                   |             |               | 0.259   |
| Male                                           | 91 (65.5)   | 72 (72.7)     |         |
| Female                                         | 48 (34.5)   | 27 (27.3)     |         |
| Body weight, kg                                | 62.2 ± 10.4 | 62.4 ± 11.0   | 0.891   |
| APACHE II score on ICU admission               | 19.0 ± 8.9  | 22.5 ± 8.4    | 0.002   |
| SOFA score on ICU admission                    | 6.6 ± 3.5   | 7.9 ± 3.8     | 0.008   |
| Underlying disease, n (%)                      |             |               |         |
| Diabetic mellitus                              | 25 (18.0)   | 28 (28.3)     | 0.081   |
| Chronic cardiac dysfunction                     | 26 (18.7)   | 26 (26.3)     | 0.203   |
| Chronic obstructive pulmonary disease           | 16 (11.5)   | 15 (15.2)     | 0.439   |
| Chronic renal insufficiency                     | 11 (7.9)    | 16 (16.2)     | 0.062   |
| Chronic hepatic insufficiency                   | 4 (2.9)     | 7 (7.1)       | 0.208   |
| Solid tumor                                    | 22 (15.8)   | 25 (25.3)     | 0.098   |
| Haematological malignancy                      | 1 (0.7)     | 2 (2.0)       | 0.572   |
| Immune compromised, n (%)                      |             |               |         |
| Immunosuppressant therapy                      | 4 (2.9)     | 6 (6.1)       | 0.327   |
| HIV infection                                  | -           | 1 (1.0)       | 0.416   |
| Neutropenia                                    | 1 (0.7)     | 2 (2.0)       | 0.572   |
| Source of candidiasis, n (%)                   |             |               | 0.999   |
| Blood culture                                  | 135 (97.1)  | 96 (97.0)     |         |
| Other sterile site                             | 5 (3.6)     | 5 (5.1)       | 0.745   |
| Pathogenic *Candida* species, n (%)            |             |               |         |
| *C. albicans*                                  | 55 (39.6)   | 38 (38.4)     | 0.893   |
| *C. tropicalis*                                | 21 (15.1)   | 11 (11.1)     | 0.443   |
| *C. glabrata*                                  | 15 (10.8)   | 18 (18.2)     | 0.128   |
| *C. parapsilosis*                              | 20 (14.4)   | 18 (18.2)     | 0.475   |
| Initial antifungal therapy                     |             |               | 0.004   |
| Strategies, n (%)                              |             |               |         |
| empirical therapy                              | 66 (47.5)   | 35 (35.4)     | 0.041   |
| pre-emptive therapy                            | 37 (26.6)   | 35 (33.4)     | 0.155   |
| Targeted therapy                               | 36 (25.9)   | 29 (29.3)     | 0.658   |
| Categories, n (%)                              |             |               | 0.348   |
| fluconazole                                    | 54 (38.8)   | 34 (34.3)     | 0.499   |
| caspofungin                                    | 34 (24.5)   | 21 (21.2)     | 0.640   |
| voriconazole                                   | 22 (15.8)   | 25 (25.3)     | 0.098   |
| Susceptibility, n (%)                          |             |               |         |
| susceptible                                    | 122 (87.8)  | 89 (89.9)     | 0.682   |
| completely resistant                           | 9 (6.5)     | 6 (6.1)       | 0.999   |
| Duration, days                                 | 8.0 (10.0)  | 6.0 (11.0)    | 0.428   |
| Drug Adjustment, n (%)                         | 62 (44.6)   | 54 (54.5)     | 0.149   |

Procedures within 2 weeks prior to diagnosis, n (%)

- Life-sustaining treatments ≥ 24 h
objective and valuable. Additionally, we are not targeted to specific populations for analysis, such as bone marrow transplantation, leukemia, or liver transplantation. Therefore, prophylaxis was not discussed here. This study revealed that the initial empirical antifungal therapy can reduce hospital mortality and have longer hospital duration for patients with severe ICIs compared with the pre-emptive therapy. The appropriate initial antifungal therapeutic strategy chosen was an independent predicting factor for the prognosis of severe ICIs. It seemed that initial empirical antifungal therapy could be critical to decrease hospital mortality.

It has been recognized that early presumptive antifungal therapy is associated with improved clinical outcomes and reduced mortality of ICIs [18–20]. We also found similar results that empirical antifungal therapy

| Procedure                                      | Hospital Mortality | Hospital Duration | p-Value |
|------------------------------------------------|-------------------|------------------|---------|
| Invasive mechanical ventilation               | 109 (78.4)        | 87 (87.9)        | 0.084   |
| Vasopressor                                    | 38 (27.3)         | 33 (33.3)        | 0.389   |
| Renal replacement therapy                      | 7 (5.0)           | 12 (12.1)        | 0.055   |

Catheterization, n (%)^i:
- **Central venous**: 113 (81.3) vs. 87 (87.9), p = 0.210
- **Indwelling arterial**: 24 (17.8) vs. 21 (21.9), p = 0.501
- **Drainage tube**: 53 (38.1) vs. 38 (38.4), p = 0.999
- **Urethral**: 101 (73.2) vs. 81 (81.8), p = 0.160

Gastrointestinal dysfunction, n (%)^l:
- 79 (56.8) vs. 54 (54.5), p = 0.791

Total parenteral nutrition, n (%):
- 70 (50.4) vs. 54 (54.5), p = 0.599

Surgery, n (%):
- 60 (43.2) vs. 35 (35.7), p = 0.283

Abdominal:
- 39 (28.1) vs. 25 (25.3), p = 0.659

Procedures at diagnosis, n (%):
- **APACHE II score**: 18.8 ± 8.5 vs. 22.7 ± 7.0, p = 0.000
- **SOFA score**: 6.4 ± 3.6 vs. 7.8 ± 3.8, p = 0.003
- **Vasopressor**: 37 (26.6) vs. 39 (29.4), p = 0.048

Catheterization, n (%)^j:
- **Central venous**: 88 (64.2) vs. 76 (77.6), p = 0.031
- **Indwelling arterial**: 20 (14.8) vs. 13 (13.5), p = 0.850
- **Drainage tube**: 40 (29.6) vs. 32 (34.0), p = 0.563
- **Urethral**: 97 (70.3) vs. 79 (79.8), p = 0.132

Central venous catheter removed within 48 h after first positive sample obtained, n (%):
- 92 (66.2) vs. 70 (70.7), p = 0.484

Drainage catheter removed within 48 h after first positive sample obtained, n (%):
- 19 (13.7) vs. 8 (8.1), p = 0.216

Immunopotentiation therapy, n (%)^k:
- 55 (39.6) vs. 51 (51.5), p = 0.085

Continuous variables are expressed as the mean ± SD or medians (IQR). All the other data are raw numbers (%).

**APACHE II** Acute Physiology and Chronic Health Evaluation II, **SOFA** sequential organ failure assessment

^aAll patients corresponding to the NYHA standards of level II or higher

^bAll patients receiving long-term hemodialysis

^cAs described according to the APACHE II criteria: biopsy-proven cirrhosis and documented portal hypertension; episodes of past upper gastrointestinal bleeding attributed to portal hypertension; or prior episodes of hepatic failure/encephalopathy/coma

^dVariables included steroid therapy, which defined as >0.5 mg/(kg · day)^−1 prednisone over 1 month (n = 7), cancer chemotherapy (n = 6), post-solid organ transplant immunosuppression (n = 1), allogeneic bone marrow transplantation or allogeneic haematopoietic stem cell transplantation (n = 1), and tumor necrosis factor therapy (n = 1) within 3 months prior to study entry

^eDiagnostic confirmation of other sterile sites was based on positive fluid culture from a normally sterile site (cerebral spinal fluid, ascitic fluid or pleural fluid) in 10 (3.7%) cases and on histopathology in one patient (0.3%); Diagnosis was confirmed by candidaemia combined with positive culture from a normally sterile site in 3 (1.1%) cases

^fC. tropicalis, C. glabrata, and C. parapsilosis were the most prevalent non-C. albicans species isolated, which were identified in >98% of samples

^gFirst-line treatment comprised a single agent in 264/268 (98.5%) patients, most commonly fluconazole (101/268; 37.7%), caspofungin (64/268; 23.9%), and voriconazole (49/268; 18.3%)

^hVariables included patients who were catheterized when the first positive samples were collected

^iVariables included immunoglobulin and thymosin

^jVariables included haemorrhage, food intolerance, perforation, surgery, acalculous cholecystitis or intra-abdominal hypertension

^kVariables included immunoglobulin and thymosin

Table 4: Risk factors for hospital mortality in 268 ICI patients receiving antifungal therapy in the China-SCAN study based only on patients who died in hospital or completed treatment and were discharged at their physician’s discretion (Continued)
Empirical vs Pre-emptive (empirical: pre-emptive: targeted) Initial antifungal therapy strategies

**Table 5** Variables included in univariate logistic regression and significant associated (P < 0.01) with hospital mortality in 268 ICU patients receiving antifungal therapy in the China-SCAN study based only on patients who died in hospital or completed treatment and were discharged at their physician's discretion.

| Variables                                      | Survivors N = 139 | Non-survivors N = 99 | P-value |
|------------------------------------------------|-------------------|----------------------|---------|
| Age, years                                     | 58.6 ± 20.6       | 66.0 ± 19.8          | 0.006   |
| APACHE II score on ICU admission               | 19.0 ± 8.9        | 22.5 ± 8.4           | 0.002   |
| SOFA score on ICU admission                    | 6.6 ± 3.5         | 7.9 ± 3.8            | 0.008   |
| APACHE II score at diagnosis                   | 18.8 ± 8.5        | 22.7 ± 7.0           | 0.000   |
| SOFA score at diagnosis                        | 6.4 ± 3.6         | 7.8 ± 3.8            | 0.003   |
| Initial antifungal therapy strategies          | 66 : 37 : 36      | 35 : 35 : 29         | 0.004   |

**Table 6** Multivariate analysis for hospital mortality in 268 ICU patients receiving antifungal therapy in the China-SCAN study with APACHE II and SOFA score on ICU admission as independent factors.

| Variables                                      | B      | SE     | Wald's coefficient | OR     | 95% CI for OR Lower | OR     | 95% CI for OR Upper | P-value |
|------------------------------------------------|--------|--------|--------------------|--------|---------------------|--------|---------------------|---------|
| APACHE II score on ICU admission               | 0.046  | 0.016  | 8.389              | 1.047  | 1.015               | 1.080  | 0.004               |         |
| Initial antifungal therapy strategies          |        |        |                    |        |                     |        |                     |         |
| (empirical : pre-emptive : targeted)           |        |        |                    |        |                     |        |                     |         |
| Empirical : Pre-emptive                        | -1.117 | 0.363  | 9.449              | 0.327  | 0.160               | 0.667  | 0.002               |         |

It has been shown that the lack of experience in treatment leading to improper drug selection could be an important risk factor for poor prognosis [24]. The results of this study showed that during the initial antifungal treatment, the empirical therapy group selected more fluconazole; the pre-emptive therapy group selected more caspofungin; and the targeted therapy group selected more voriconazole, which were partly consistent with the recommended guidelines [12, 13]. In addition, there was no statistical significance in antifungal drug sensitivity and the duration of drug administration among these three strategies. This result suggested that depending on the combination of local epidemiological survey data and guidelines, pre-emptive and targeted antifungal therapy had no advantage than empirical therapeutic strategy in clinical efficacy and safety. Interestingly, we also found that the drug adjustments for pre-emptive therapy after the initial antifungal therapy was significantly higher compared with the empirical therapy and targeted therapy groups (P = 0.017) in this study. It further confirmed the credibility and feasibility of empirical antifungal therapy, which could be another important reason for empirical therapy that significantly improves the clinical prognosis of ICI patients. Conversely, delaying the start time of the antifungal infection treatment is undoubtedly detrimental.

It has been demonstrated that critically ill ICU patients have complicated conditions. In the initial treatment strategy of the antifungal treatment evaluation process, including the basic conditions of the patient (severity of illness, invasive operation, gastrointestinal function, recent surgical history, previously selected types of antibiotics and antifungal drugs and other factors) is important as these conditions are likely to have an impact on prognosis and assessment. To further enhance the objectivity and accuracy of the assessment, all these risk factors are compared using statistical analysis. Diagnostic confirmation was based solely on at least one positive blood culture in 257 (95.9%) cases. Only 27 (10.8%) cases finally proved incidence of a catheter-related blood stream infection, and the reason for the lower incidence has been reported by Hu, et al on behalf of China-SCAN [25]. There was no significant difference among the three different strategies for abdominal sources.
of candidiasis. Maybe the absence of adequate abdominal source control caused late abdominal fungal infections, which led to a more targeted antifungal therapy after direct etiological evidence was found rather than early administration. Regarding the pathogenic Candida species, there was no significant difference [26]. Similar to other studies [27], the proportion of non-albicans Candida infection (60.1%) was higher than that of Candida albicans (39.9%) in this study population. Fortunately, the vast majority of Candida detected was susceptible to antifungal drugs. Because all patients in this study were diagnosed with ICI during hospitalization in ICU and the limitation of ICI occurrence influenced survival time after infection, it was more useful to compare the length of ICU and total hospitalization time to reflect the actual effectiveness of antifungal infection treatment. Therefore, Kaplan-Meier survival analysis revealed that ICI patients with initial pre-emptive antifungal therapy and initial targeted antifungal therapy were associated with a reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation of fungal infection (log-rank test: \( P = 0.021 \)). This indicator was strongly demonstrated that early appropriate empirical antifungal therapy, which helps prolong the hospital survival time of patients with severe ICIs, may lay a solid foundation for reduced hospital mortality.

Our study has several limitations. First, this study only included patients diagnosed with ICI, which may provide a more clear influence of different strategies on ICIs. However, we did not evaluate the role of different strategies for the patients with a suspected ICI but no ICI confirmation. Second, although the China-SCAN study was a multi-center, observational study, the results of this study were based on statistical analysis rather than a prospective study on treatment strategies. Therefore, another RCT is needed to further confirm the direct effect of different therapeutic strategies on bacteriological and clinical prognosis. Third, 59 patients withdrew from or decided to forego comprehensive treatment in this study, 29 of whom died in the hospital and 30 were discharged at their request. The ICU or hospital mortality rate listed here was based only on patients who died in the hospital or completed treatment and were discharged at their physician’s discretion. We do not exclude the fact that this might have impacted the results of our statistical analysis.

Table 7 Multivariate analysis for hospital mortality in 268 ICI patients received antifungal therapy in the China-SCAN study with APA-CHE II and SOFA score at ICI diagnosis as independent factors

| Variables                          | B     | SE   | Wald’s coefficient | OR    | 95% CI for OR Lower | Upper | P-value |
|------------------------------------|-------|------|--------------------|-------|---------------------|-------|---------|
| Initial antifungal therapy strategies (empirical : pre-emptive : targeted) | 8.068 | 0.018 | 7.706              | 0.351 | 0.168 0.735         | 0.006 |         |
| Empirical : Pre-emptive            | -1.047| 0.377|                    | 0.351 | 0.168 0.735         | 0.006 |         |

Conclusions

In summary, the initial antifungal treatment strategy formulation is an independent risk factor for the prognosis of patients with an ICI. Selecting the appropriate timing of the initial antifungal treatment could help improve the clinical cure rate, reduce the incidence of persistent fungal infection, and lower hospital mortality in patients with severe ICIs. This finding is consistent with the treatment strategy of resistance to bacterial infections. However, this conclusion has yet to be confirmed by a prospective RCT study in the future.

Abbreviations

APACHE II score: Acute Physiology and Chronic Health Evaluation II score; China-SCAN: China Survey of Candidiasis in the ICU; ICIs: Invasive Candida infections; ICUs: Intensive care units; IFI: Invasive fungal infection; PCR: Polymerase-chain reaction; RCT: Randomized control trial; SOFA score: Sequential organ failure assessment score

Acknowledgements

We thank all the members of the China-SCAN Team. Shengjing Hospital, Affiliated to China Medical University; West China Hospital, Sichuan University; The Second Affiliated Hospital of Zhejiang University School of Medicine; Henan Provincial People’s Hospital; Tiantan Hospital Affiliated to Capital Medical University; The First Affiliated Hospital of Soochow University; General Hospital of Ningxia Medical University; Jiangsu Subei People’s Hospital; The First Affiliated Hospital of Harbin Medical University; Zhongnan Hospital of Wuhan University; The First Affiliated Hospital of Nanjing University Medicine School; Affiliated Hospital of Nantong University Hospital; Zhongda Hospital, Southeast University; The First Affiliated Hospital of Fujian Medical University; Zhongshan Hospital, Fudan University; The First Affiliated Hospital of Lanzhou University; The First Affiliated Hospital of Zhengzhou University; Affiliated Hospital of Guizhou Medical College; Xuzhou Central Hospital; Peking Union Medical College Hospital; Ningbo First Hospital; The Second Affiliated Hospital of Soochow University; General Hospital of Ningxia Medical University; Jiangsu Subei People’s Hospital; The First Affiliated Hospital of Harbin Medical University; Zhongnan Hospital of Wuhan University; The First Affiliated Hospital, SUN YAT-SEN University; Qiu Hospital of Shandong University; First Affiliated Hospital of Kunming Medical University; The First Affiliated Hospital of Nanjing University Medical School; Tiantan Hospital Affiliated to Capital Medical University; Beijing Tongren Hospital, Capital Medical University; The First Hospital of China Medical University; The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Wenzhou Medical College; First Affiliated Hospital of Medical College of Xian Jiaotong University; Chinese PLA General Hospital; The Second Affiliated Hospital of Harbin Medical University; Peking University, Shenzhen Hospital; Shanghai Changzheng Hospital; Xiangya Hospital Central-South University; The First Affiliated Hospital with Nanjing Medical University; First Affiliated Hospital of Dalian Medical University; Hebei Medical University Fourth Hospital; Tiantan First Center Hospital; The First Affiliated Hospital of Guangzhou Medical University; Hainan Provincial People’s Hospital; The Affiliated Hospital of Medical College Qingdao University; Wuxi People’s Hospital; The First Teaching Hospital of Xiangyang Medical University; Nanjing First Hospital; The Second Hospital of Jilin University; Wuhan Union Hospital; Tongji Medical College of Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Zhejiang Hospital; Shandong Provincial Hospital; Rui Jin Hospital, Shanghai Jiaotong University School of Medicine; Southwest Hospital; The First Hospital of Jilin University; First People’s Hospital of Foshan;
The First Affiliated Hospital of Medical College, Shiehe University; Shiehe People’s Hospital; Qinghai Provincial People’s Hospital; The First Affiliated Hospital of Chongqing Medical University; Research Center for Medical Mycology, Peking University First Hospital, Peking University.

Funding
This work was supported by Merck Sharp & Dohme China, who sponsored the study. Medical writing and editing assistance were supported by Merck & Co., Inc., White house Station, NJ, USA.

Availability of data and materials
All data generated or analyzed during this study are from the databases of the China-SCAN study and included in this published article (Invasive candidiasis in intensive care units in China: a multi-center prospective observational study. J Antimicrob Chemother 2013, 68: 1660–1668). All data generated or analyzed during this study are available from the corresponding author on reasonable request.

Authors’ contributions
NC, DL, HW, HQ, and RL designed the study. NC and HW contributed to the manuscript development. LS participated in medical writing and data analysis. All authors served as study investigators at their hospital sites and reviewed the final manuscript. All authors read and approved the manuscript.

Consent to publication
Not applicable.

Competing interests
Haibo Qiu is a speaker for Pfizer and MSD China, and has received research grants from Pfizer, MSD China and Xian-Janssen. The remaining authors have no conflicts of interest to disclose. The funders participated in the design of the study, but had no role in study management, monitoring, data management, statistical analysis or development of this article. Authors accept direct responsibility for this paper.

Ethics approval and consent to participate
We accepted the central ethics committee (Ethics Committee of Zhongda Hospital of Southeast University) review as other participating hospitals, and we accepted the central ethics committee (Ethics Committee of Zhongda Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China. Nanjing Zhongda Hospital, Southeast University School of Medicine, Nanjing, China. Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing, China.

Received: 15 November 2016 Accepted: 17 January 2017

Published online: 23 January 2017

References
1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3(11):685–702.
2. Shoham S, Marwaha S. Invasive fungal infections in the ICU. J Intensive Care Med. 2010;25(2):78–92.
3. Kullberg BJ, Andreat MC. Invasive Candidiasis. N Engl J Med. 2015;373(15):1445–59.
4. Guery BP, Andreat MC, Auzinger G, Azoulay E, Borges SA, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med. 2009;35(1):55–62.
5. Vincent JL, Reillo J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sak Y, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(11):1232–9.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clinical Infect Dis. 2004;39(3):509–17.
7. Tabah A, Koulenti D, Laupland K, Misser B, Valles J, Bruzzi de Carvalho F, Paiva JA, Calak N, Ma X, Eggimann P, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care unit: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38(12):1930–45.
8. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended Prevalence of Infection in ICUs:1. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39(4):665–70.
9. Azoulay E, Dupont H, Tabah A, Lothrholary O, Stahl JP, Francais A, Martin C, Guidet B, Timst JF. Systemic antifungal therapy in critically ill patients without invasive fungal infection. Crit Care Med. 2012;40(3):813–22.
10. Guillaumezqoon Q, Gilliepie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pföhr M, Diekema D. Attributable mortality of nosocomial candidemia, revisited. Clinical Infect Dis. 2003;37(9):1172–7.
11. Guo F, Yang Y, Kang Y, Zang B, Cui W, Qin B, Qin Y, Fang Q, Qin T, Jiang D, et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother. 2013;68(7):1660–8.
12. Pappas PG, Kauffman CA, Andes D, Benjamin Jr DK, Calandra TF, Edwards Jr JE, Filler SG, Fisher JF, Kulberg BJ, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infect Dis. 2009;48(5):503–35.
13. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lothrholary O, Meersseman W, Akova M, Andreat MC, Arken-Alkadi S, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18 Suppl 7:19–37.
14. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Synam RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644–55.
15. Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, Utande-Vazquez A, Gonzalez de Molina FJ, Blasco-Navalporto MA, et al. Usefulness of the “Candida score” for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med. 2009;37(5):1624–33.
16. Micoczi A, Bucanee G. Prophylaxis and treatment of bacterial infections: do we need new strategies? Rev Clin Exp Hematol. 2005;9(2):E4.
17. Liberati A, D’Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev. 2009;4(8):CD00022.
18. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43(1):25–31.
19. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–46.
20. Puj-Asensio M, Pernan J, Zaragoza R, Garnacho-Montero J, Martin-Mazuelos E, Cuenca-Estrella M, Almirante B, Prospective Population Study on Candidemia in Spain P, Hospital Infection Study G, Medical Mycology Study Group of the Spanish Society of Infectious Diseases O, et al. Impact of therapeutic strategies on the efficacy of candidemia in the ICU. Crit Care Med. 2014;42(6):1423–32.
21. Schuster MG, Edwards Jr JE, Sobel JD, Darouiche RO, Karcher AW, Hadley S, Stotman G, Panzer H, Biswas P, Rev JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med. 2008;140(9):839–90.
22. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Bette B, Barron MA, Schuster M, Judson MA, Revankar SG, Cairns JF, et al. MSG-01: A randomized, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the intensive care setting. Clin Infect Dis. 2014;59(9):1219–26.
23. Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G, Ozgunes I, Valia JC, Eggimann P, Leon C, et al. A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Clin Infect Dis. 2015;61(1):1671–8.
24. Dimopoulos G, Antonopoulou A, Armaganidis A, Vincent JL. How to select an antifungal agent in critically ill patients. J Crit Care. 2013;28(5):717–27.
25. Hu B, Du Z, Kang Y, Zang B, Cui W, Qin B, Fang Q, Qu H, Li J. Catheter-related Candida bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study. BMC Infect Dis. 2014;14:594.
26. Bassetti M, Righi E, Ansaldi F, Merelli M, Scarparo C, Antonelli M, Garnacho-Montero J, Diaz-Martín A, Palacios-Garcia I, Luzzati R, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015;41(9):1601–10.
27. Deorukhkar SC, Saini S, Mathew S. Non-albicans Candida Infection: An Emerging Threat. Interdisciplinary perspect Infect Dis. 2014;2014:615958.